natgillin/translations-raw huggingface dataset:
All these drawbacks are eliminated according to the invention by a method for producing expanded metal profiles as claimed in claim 1. 
Svi ovi nedostaci se uklanjaju u skladu s ovim izumom pomoću postupka za proizvodnju rastegnutih metalnih profila, kao što je specificirano u patentnom zahtjevu 1.
A compound of Formula (I) or pharmaceutically acceptable salt, solvate, or solvate of salt, thereof, wherein: 
Spoj s Formulom (I) [image] ili njegova farmaceutski prihvatljiva sol, solvat ili solvat soli, naznačen time da: X je N ili CH;
Non-linear regression analysis of the binding curves was performed in GraphPad Prism. 
Analiza ne-linearne regresije krivulja vezivanja je provedena u GraphPad Prism.
The basin according to one or more of the preceding claims, characterized in that said framework (23) is provided by a plurality of parallelepipedal modules (26). 
Osnova sukladno jednom ili više prethodnih zahtjeva, naznačena time što je navedeni okvir (23) osiguran pomoću više paralelopipednih modula (26).
Process according to claim 7, characterized in that the amount of calcium in the ingredients used for the pharmaceutical solution, namely the chelate powder, in particular DOTA, water and meglumine, is less than 50 ppm, advantageously less than 20 ppm. 
PPI i time da je količina kalcija u sastojcima koji se koriste za farmaceutsku otopinu, odnosno u kelatnom prahu, naročito DOTA, vodi i megluminu, manja od 50 ppm, poželjno manja od 20 ppm.
determining whether the PAA prodrug dosage needs to be adjusted based on whether the PAA:PAGN ratio falls within a target range, where a PAA:PAGN ratio below the target range indicates that the dosage potentially needs to be increased and a PAA:PAGN ratio above the target range indicates that the dosage needs to be decreased, and 
određivanje da li prva doza gliceril tri-[4-fenilbutirata] (HPN-100) treba biti prilagođena na temelju toga da li omjer PAA:PAGN spada u okviru ciljanog opsega od 1 do 2,5, pri čemu omjer PAA:PAGN ispod ciljanog opsega pokazuje da doza treba biti povećana i omjer PAA:PAGN iznad ciljanog opsega pokazuje da doza treba biti smanjena, i
Fatty acid esters have also been used in heat curable powder coatings. 
Esteri masnih kiselina su također bili upotrijebljeni u praškastim prevlakama koje se otvrdnjavaju pomoću topline.
The extended release tablet formulation according to any of the previous claims, wherein the contained amount of pramipexole or pharmaceutically acceptable salt thereof is sufficient to provide a daily dose administered at one time, preferably the amount of pramipexole or pharmaceutically acceptable salt thereof is of about 1% to about 10% by weight, more preferably of about 2% to about 5% by weight. 
Formulacija tablete produljenog oslobađanja u skladu s bilo kojim prethodnim zahtjevom, naznačena time, da je sadržana količina pramipeksola ili njegove farmaceutski prihvatljive soli dovoljna da osigura dnevnu dozu primjenjenu odjednom.
In one embodiment the at least one further antigen is selected from the group consisting of Pertussis Toxin, Filamentous Haemaglutinin, Pertactin, a Fimbrial Agglutinogen, Diphtheria Toxoid, Tetanus Toxoid, at least one conjugated saccharide antigen from N. meningitidis, Hepatitis B surface antigen, Inactivated Polio Virus (IPV) and a conjugated saccharide antigen from Haemophilus influenzae b. 
Fermentacijski postupak u skladu s patentnim zahtjevom 16, naznačen time što se antigen bira iz skupine koju čine toksin hripavca, filamentozni hemaglutinin, pertaktin, fimbrijski aglutinogen, difterijski toksoid, tetanusni toksoid, konjugirani saharidni antigen iz bakterije N. meningitidis, površinski antigen izu virusa hepatitisa B, inaktivirani polio virus (IPV) i konjugirani saharidni antigen iz bakterije Haemophilus influenzae b.
When assembling the flushing unit with tubular member, the inner tube will be connected to the first guiding passage, and the outer tube will be connected to the fluid channel(s). 
Kada se sastavlja jedinica za ispiranje sa cijevnim elementom, unutarnja cijev će se spojiti na prvi prolaz za vođenje, a vanjska cijev će se spojiti na kanal(kanale) za fluid.
Preferably, the reagent is selected from the group consisting of an antibody, a fragment of an antibody, and an antibody derivative. 
Postupak prema zahtjevu 8, naznačen time, da je reagens odabran iz skupine koja se sastoji od protutijela, fragmenta protutijela ili derivata protutijela,
Colloidal silicon dioxide 
Koloidni silicijev dioksid
Examples of production of amino acid substitutions in proteins which can be used for obtaining muteins of IL-18BP polypeptides or proteins, or muteins of viral IL-18BPs, for use in the present invention include any known method steps, such as presented in US patents 4,959,314, 4,588,585 and 4,737,462, to Mark et al; 5,116,943 to Koths et al., 4,965,195 to Namen et al; 4,879,111 to Chong et al; and 5,017,691 to Lee et al; and lysine substituted proteins presented in US patent No. 4,904,584 (Shaw et al). 
Trp Met Primjeri zamjene aminokiselina u proteinima koji se koristite za stvaranje muteina polipeptida ili proteina IL-18BP ili muteina viralnog IL-18BP, a koji su korisni za ovaj izum mogu uključivati bilo koje poznate postupke poput onih koji su navedeni u Američkim patentima 4,959,314; 4,588,585 i 4,737,462 od Mark i sur.; 5,116,943 od Koths i sur.;
formulating non-glycosylated recombinant human G-CSF with an acetate or glutamate buffer and sorbitol to obtain an aqueous buffered G-CSF composition, wherein the amount of G-CSF is in the range of from 0.1 mg/ml to 8.0 mg/ml and wherein said composition has a volume of from 100 ml to 8 I; 
(a) formuliranje neglikoziliranog rekombinantnog ljudskog G-CSF s acetatnim ili glutamatnim puferom i sorbitolom, za dobivanje vodenog puferiranog G-CSF-sastava, pri čemu je količina tog G-CSF u rasponu od 0,1 mg/ml do 8,0 mg/ml 1 pri čemu spomenuti sastav ima volumen od 100 ml do 8 L;
R6A and R7A are taken together to form a moiety selected from the group consisting of an optionally substituted and an optionally substituted wherein the oxygens connected to R6A and R7A, the phosphorus and the moiety form a six-membered to ten-membered ring system; 
A i R7A su uzeti zajedno tako da tvore dio odabran iz skupine koja sadrži po izboru supstituiran i po izboru supstituiran pri čemu atomi kisika spojeni na R6A i R7A, fosfor i ostatak tvore šesteročlani do deseteročlani prstenski sustav;
Preferably, the receiving step comprises receiving a notification from an HLR scanner, the HLR scanner being arranged to detect a location update message received by a Home Location Register (HLR) to which the subscribed device is subscribed, the location update message corresponding to the change in current location of the subscribed device. 
Postupak prema zahtjevu 1 i zahtjevu 2, pri čemu prijemni korak obuhvaća prijem notifikacije od HLR skenera, a HLR skener je podešen da detektira poruku o promjeni lokacije koju prima Registar Vlastitih Pretplatnika (engl.
Headset apparatus according to any of claims 23 to 25 in which said harness includes connector means to which a retention strap is connectable and from which said strap may extend across a part of the head of a user thereby to strap an aforesaid earshell to the head of the user, wherein the connector means is defined by a portion of the harness shaped to be raised and separated from the surface of the earshell when the harness is fitted thereto, thereby to enable said strap to pass between the strap connector means and the surface of the earshell over which the connector is raised thereby to permit attachment of said strap thereto. 
Slušalice prema bilo kojem od zahtjeva 23 do 25, naznačene time, da navedena tehnička oprema obuhvaća konektor na koji se može spojiti zadržna pasica, te s kojega se navedena pasica može protezati preko dijela glave korisnika, čime pripasuje navedenu školjku za uho na glavu korisnika, dok je konektor definiran pomoću dijela tehničke opreme oblikovanog tako, da se uzdiže 1 odvaja od površine školjke za uho, kada je za nju pričvršćena tehnička oprema, čime se omogućava navedenoj pasici da prolazi između konektora pasice i površine školjke za uho preko koje se konektor uzdiže, a time se dopušta priključenje navedene pasice.
A composition suitable for control of diseases caused by phytopathogens comprising a synergistically effective amount of 
PATENTNI ZAHTJEVI Pripravak pogodan za kontrolu bolesti uzrokovanih fitopatogenima koji se sastoji od:
The method of claim 3, wherein the composition administered orally, intrathecally, enterally, or intravenously. The method of claim 23, wherein the composition is administered orally and further comprises cow's milk, human breast milk, infant formula or water. 
dC ili dT, namijenjeni upotrebi u skladu s patentnim zahtjevom 10, naznačeni time što se pripravak primjenjuje oralno; te što navedeni pripravak dodatno sadrži kravlje mlijeko, majčino mlijeko, formulu za dojenčad ili vodu.
A system according to claim 11, wherein the two or more short-range phone interface units share information exchanged with the cellular base station via a single cellular hub device. 
Sustav sukladno zahtjevu 1, naznačen time, da dva ili više jedinica sučelja telefona kratkog dometa dije informacije putem mobilnog hub uređaja.
The moving bed heat exchanger of claim 4, wherein a distance between a lower one of the plates and the plate above the lower plate is determined by an angle of repose of the hot solids and/or ash. 
Sustav prema zahtjevu 5, naznačen time da se udaljenost između otvora u prvoj ploči i/ili drugoj ploči određuje pomoću kuta mirovanja vrućih krutih tvari i/ili pepela.
Pleuromutilin derivatives for the treatment of diseases mediated by microbes 
DERIVATI PLEUROMUTILINA ZA LIJEČENJE BOLESTI POSREDOVANIH MIKROBIMA
growing and maintaining the stable cells. 
Uzgoja i održavanja stabilnih stanica .
contacting the antigen presenting cells of step (iii) with a T-cell to evaluate the ability of the peptide to stimulate the T-cells; and 
stavljanja u kontakt stanice za predočavanje antigena iz koraka (iii) s T-stanicom kako bi se procijenilo sposobnost peptida da simulira T-stanicu; i
This makes the building concept very flexible. 
Ovo čini koncept gradnje vrlo fleksibilnim.
The DOTA-bound anti-P-cadherin antibody according to claim 12 or 13, wherein the mole ratio of the anti-P-cadherin antibody to DOTA is 1: 0.1 to 1: 4.5, preferably 1: 0.5 to 1: 3. 
DOTA-vezano anti-P-kadherin antitijelo u skladu s patentnim zahtjevom 12 ili 13, naznačeno time, da je molni omjer anti-P-kadherin antitijela na DOTA od I: 0,1 do 1: 4,5, poželjno 1:0,5 do 1: 3.
b is absent or represents C1-C3alkylene, C1-C3alkenylene or a group selected from -CH2NH-, -CH2O-, and -CH2S-, said group being linked to G via the nitrogen, oxygen or sulfur atom; or when L1 is N(R5)E and E is an amino protecting group said protecting group is removed and the deprotected intermediate is reacted with a compound of formula III as defined above. 
A4b je odsutan ili predstavlja C,-Czalkilen, C,-Cxalkenilen ili skupinu koju se bira između -CH,NH-, 1 - CH,S-, gdje je navedena skupina vezana na G preko atoma dušika, kisika ili sumpora; ili kada je LI N(RSJE, a E je zaštitna skupina za amino, navedenu zaštitna skupina se uklanja, a međuprodukt s kojeg je skinuta zaštita reagira sa spojem formule III kao što je definirano gore.
After concentration using a rotary evaporator, ˜1 L of clear light amber oil remained. 
Poslije koncentriranja primjenom rotacijskog isparivača, ostalo je - 1I bistrog svijetlo jantarastog ulja.
In a third aspect of the seventh embodiment, the concentration of the colistimethate sodium ranges from 85 to 113 mg A/mL. 
Uređaj sukladno patentnom zahtjevu 2, pri čemu koncentracija kolistimetat natrija u rasponu od 85 do 113 mg A/mL.
The oligomer according to any one of embodiments 1 - 19, wherein the linker group between the second and third regions comprises a group selected from phosphodiester, a phosphorothioate, and phosphorodithioate or a boranophosphate group, such as a phosphodiester group. 
Oligomerni spoj prema bilo kojem od patentnih zahtjeva 1 do 15, naznačen time, da kovalentna poveznica između druge i treće regije obuhvaća skupinu odabranu od fosfodiestera, fosforotioata te fosforoditioata ili boranofosfatne skupine, poput fosfodiesterske skupine.
wherein the carbon atom to which R1, R2, and R3 are attached is a chiral center, having an epimeric ratio of at least about 96:4. 
Kompozicija prema patentnom zahtjevu 20, gdje, atom ugljika za koji su vezani R', R? i R', je hiralni centar, koji ima epimerni odnos od najmanje 96:4.
The process of claim 7, wherein the solvent is an alcohol. The process of claim 8, wherein the alcohol is selected from the group consisting of methanol, ethanol and isopropanol. 
Postupak prema zahtjevu 6, gdje je otapalo odabrano iz skupine koja se sastoji od vode, izopropanola, metanola, etanola, te prikladne smjese dvaju ili više prethodno navedenih otapala.
The compound of any one of claims 1 to 3, which is 
Spoj bilo kojeg od patentnih zahtjeva 1 do 3, koji je ci
and R′1 are the same or different, and each represents an aryl group, a heteroaryl group, or R1 and R′1, together with the carbon atom to which they are linked, form a fused ring structure of formula: 
R; 1 R', su isti ili različiti, te svaki predstavlja arilnu skupinu, heteroarilnu skupinu, ili R, i R',, zajedno sa atomom ugljika na koji su vezani, formiraju kondenziranu prstenastu strukturu formule:
In cats, 10 mg/kg of the product caused a 79% increase in W duration during a 6 h recording period (p<0.01). 
Kod mačaka je 10 mg/kg proizvoda dovelo do 79%-tnog povećanja u trajanju budnosti (W) za vrijeme bilježenja od 6 sati (p < 0,01).
The pharmaceutical composition of any one of claims 5 to 7, comprising a therapeutically effective amount of said active ingredient 
Farmaceutska smjesa prema zahtjevu 4 ili 5, koja sadrži terapijski učinkovitu količinu spomenute djelatne tvari.
The liquefied gas treatment system according to claim 2, wherein a gas-liquid separator is installed to separate only a liquid component from the third stream decompressed to a gas-liquid mixed state and return the liquid component to the cargo tank. 
Sustav za obradu ukapljenog plina u skladu s bilo kojim od patentnih zahtjeva 2 do 5, naznačen time što je ugrađen separator tekućine od plina (23), koji odvaja samo tekuću komponentu od treće struje, dekomprimirane u plinsko-tekuće miješano stanje i vraća tekuću komponentu u spremnik za teret (11).
The process of claim 2 wherein R is selected from the group consisting of benzyl, acetyl, benzoyl, trifluoromethanesulfonyl, benzenesulfonyl,p-toluenesulfonyl, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, allyloxycarbonyl, benzyloxycarbonyl. 
Postupak iz patentnog zahtjeva 8, naznačen time da je R odabran iz sljedeće skupine: benzil, acetil, benzoil, trifluormethanesulfonil, benzenesulfonil, p-toluensulfonil, metoksikarbonil, etoksikarbonil, ferf-butoksikarbonil, aliloksikarbonil, benziloksikarbonil.
wherein the ability of the test compound to stimulate GIP secretion from the vertebrate enteroendocrine cell or cell capable of secreting GIP is indicative of the test compound being a GIP secretagogue. 
pri čemu sposobnost test spoja za stimuliranje GIP sekrecije iz enteroendokrine stanice kralježnjaka ili iz stanice sposobne za GIP sekreciju, pokazuje da li je test spoj postao GIP sekretogog.
As an alternative or additionally, the raw WPC material can be embossed and/or chafed/sanded in a particulate pattern to imitate natural materials such as wood or stone. 
Laminatni podni panel u skladu sa patentnim zahtjevom 6, gdje WPC materijal je reljefan i/ili izbrazdan ili izbrušen po posebnoj shemi da bi imitirao prirodne materijale kao što su drvo ili kamen.
Only small amounts of the metabolite M1 were generated. 
Stvarane su samo male količine metabolita M1.
mg of said effervescent agent. 
mg navedenog šumećeg agensa.
The method of claim 5, wherein outcome is breast cancer specific survival, event-free survival, or response to therapy. 
(1i) ishod je preživljenje specifično za rak dojke, preživljenje bez pojave Traka ili odgovor na terapiju; ili
Certain isotopically-labeled compounds of the present invention are useful in compound and/or substrate tissue distribution assays. 
Određeni izotopno označeni spojevi prikazanog izuma su korisni u ispitivanjima raspodjele spoja i/ili supstrata u tkivima.
The method of claim 4, wherein the weight ratio of carboxymethylcellulose to hydroxyethylcellulose is about 3. 
Polimerni hidrogel u skladu s patentnim zahtjevom 3, naznačen time da je težinski omjer karboksimetilceluloze naspram hidroksietilceluloze u vodenoj otopini veći od 1:1.
During the pelletization process the concentration of the active ingredient is determined by the single dose of the active agent finished in a dose unit so that the weight of the pellets containing a single dose of the active ingredient should vary between 50 to 1500 mg, preferably between 100 to 700 mg. 
Tijekom postupka granuliranja koncentracija aktivnog sastojka određuje se kao jedinična doza aktivnog sastojka u doznoj jedinici tako da težina tablete koja sadrži jednu dozu aktivnog sastojka varira između 50 do 1500 mg, poželjno između 100 do 700 mg.
is selected from hydrogen, halo and -C(O)R10; wherein R10 is methyl; and is selected from hydrogen, halo, cyano, methyl and trifluoromethyl. 
R* je odabran od sljedećih: vodik, halogen i -C(O)R'", pri čemu R'*je metil; i R/ je odabran od sljedećih: vodik, halogen, cijano, metil i trifluorometil.
Some of the compounds of the invention exist in stereoisomeric forms. 
Neki od spojeva izuma postoje u stereoizomernim oblicima.
The axle-counting device according to claim 8, wherein the full widths at half maximum of the reflection peaks of the two fiber Bragg gratings differ by 1 to 2 orders of magnitude. 
Uređaj za brojanje osovina prema zahtjevu 13, naznačen time, da se širine (FWHM) poluvrijednosti refleksijskih vrškova (P1, P2) obje Braggove rešetke (FBG1, FBG2) u vlaknu razlikuju za 1 do 2 reda veličine.
A lipid compound according to claim 11, wherein R2 and R3 are an ethyl group and a hydrogen, and X is a carboxylic acid derivative in the form of a 2-mono-glyceride. 
Lipidni spoj prema zahtjevu 11, pri čemu R2 i Rs su etil skupina i vodik, 1 X je derivat karboksilne kiseline u obliku 2-mono-glicerida.
The process according to claim 1, wherein the polyethylene composition comprises from 25 to 40 wt % of the high density polyethylene post consumer resin relative to the total weight of the polyethylene composition. 
Postupak prema bilo kojem zahtjevu od 1 do 7 naznačeno time da sastav sadrži od 0% 25 do 40 reciklirane polietilenske smole visoke gustoće u odnosu na ukupnu težinu sastava.
Separate experiments were carried out for each animal species investigated. 
Odijeljeni eksperimenti su provedeni za svaku životinjsku vrstu koja je ispitivana.
The long-term seabed-based multi-point in-situ observation system according to claim 8, characterized in that the revolving disc (16) is also provided with a deposit sampler (17). 
Sustav za dugotrajno promatranje na licu mjesta s više točaka, s bazom na morskom dnu, u skladu s patentnim zahtjevom 8, naznačen time, što je okretni disk (16) također opremljen uređajem za ispitivanje sedimentnih uzoraka (17).
The method according to claim 1 wherein in step a) the liquid ingredient mix is prepared using milk in dry form, such as milk powder 
Metoda prema patentnom zahtjevu 1, naznačena time, što se u koraku a) tekuća mješavina sastojaka priprema korištenjem mlijeka u suhom obliku, kao što je mlijeko u prahu.
The first preferred method preferably comprises the following steps: providing said first metal plate, acoustic insulation layer and second metal plate, wherein the second metal plate has been or is provided with openings, hereinafter referred to as welding openings, at locations where the locally welded joints will be provided; 
osiguravanju navedene prve metalne ploče (1), sloja zvučne izolacije (3) 1 druge metalne ploče (2), gdje druga metalna ploča ima ili su na njoj načinjeni otvori, koje se nadalje navodi kao otvore za zavarivanje (4), na mjestima gdje će se načiniti lokalno zavarene spojeve;
The unit dose of claim 1, wherein the 20mg of glatiramer acetate does not form polypeptide aggregates in the 0.5ml of aqueous pharmaceutical solution. 
Jedinična doza prema patentnom zahtjevu 1, naznačena time, da 20 mg glatiramer acetata ne tvori polipeptidne agregate u 0,5 ml vodene farmaceutske otopine.
5-[4-(2,4-Dichloro-phenylcarbamoyl)-piperidin-1-yl]-4-methyl-benzofuran-2-carboxylic acid and the stereoisomeric forms, mixtures of stereoisomeric forms or pharmaceutically acceptable salts forms thereof. 
5-[4-(2,4-Dikloro-fenilkarbamoil)-piperidin-1-il]-4-metil-benzofuran-2-karboksilnu kiselinu i stereoizomerni oblici, smjese stereoizomernih oblika i njihovi farmaceutski prihvatljivi oblici soli.
In a specific variation, the compound is of the formula (VIa) where R3 is a C1-C8 alkyl substituted with 1 to 5substituents selected from the group consisting of hydroxyl, alkoxy, acyloxy, acyl, carboxyl, carboxylalkyl, alkoxycarbonyl, and heterocyclyl. 
. Spoj patentnog zahtjeva 4, gdje R? je C,-C; alkil supstituiran sa 1 do 5 supstituenata nezavisno odabranih od grupe koja se sastoji od hidroksil, alkoksi, aciloksi, acil, karboksil, karboksilalkil, alkoksikarbonil, i heterociklil.
Its cathode is connected to the collector of a transistor 370, having its emitter connected to ground 100 and the base biased by a divider formed by two resistors 346, 344 and supplied by the collector of transistor 70. 
Katoda je spojena na kolektor tranzistora 370, koji ima emiter spojen na masu 100 i bazu upravljanu djelilom dvaju otpornika 346, 244 i napajanu kolektorom tranzistora 70.
The method of claim 15, wherein increasing the tolerability of glatiramer acetate treatment in the human patient suffering from a relapsing form of multiple sclerosis comprises reducing the frequency of an immediate post injection reaction. 
Lijek za uporabu prema bilo kojem od patentnog zahtjeva 1 ili patentnih zahtjeva 3-8, naznačen time, da jest za uporabu u smanjivanju učestalosti relapsa kod pacijenta koji pati od relapsno remitirajuće multiple skleroze.
The method of claim 8, wherein the antibiotic is selected from the group consisting of macrolide antibiotics, beta-lactam antibiotics, fluoroquinolones, aminoglycosides, and clindamycin. The method of claim 8, wherein the antifungal agent is selected from the group consisting of 1-hydroxy-2-pyridone compounds and their salts, imidazole derivatives and their salts, polyene derivatives and their salts, allylamine derivatives and their salts, triazole derivatives and their salts, morpholine derivatives and their salts, griseofulvin and related compounds, undecylenic acid and its salts, tolnaphtate and its salts, and flucytosine and its salts. 
Nifuratel, namijenjen upotrebi u skladu s patentnim zahtjevom 8, naznačen time što se navedeni najmanje jedan antifungik bira između: spojeva 1-hidroksi-2-piridona i njihovih soli, primjerice ciklopiroksa, rilopiroksa, piroktona, ciklopiroks olamina; derivata imidazola i njihovih soli, primjerice clotrimazola, ekonazola, izokonazola, ketokonazola, mikonazola, tiokonazola, bifonazola, fentikonazola i oksikonazola; derivata poliena i njihovih soli, primjerice nistatina, natamicina i amfotericina; derivata alilamina i njihovih soli, primjerice naftifina i terbinafina; derivata triazola i njihovih soli, primjerice flukonazola, itrakonazola, terkonazola i vorikonazola; derivata morfolina i njihovih soli, primjerice amorolfina i morfolina; grizeofulvina i srodnih spojeva, primjerice grizeofulvina; undecilenske kiseline i njenih soli, osobito cinkove i kalcijeve soli undecilenske kiseline; tolnaftata i njegovih soli; te flucitozina i njegovih soli.
A compound selected from the group consisting of 2-[1-(2-fluorobenzyl)-3-methylpyrrolidin-3-yl]-1H-benzimidazole-4-carboxamide; 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je odabran Iz skupine koja se sastoji od 2-[1-(2-fuorobenzil)-3-metilpirolidin-3-11]-1H-benzimidazol-4-karboksamida;